Capital Rx Drug Recall Report

JULY 2024

Welcome to the Capital Rx Drug Recall Report. This report is designed to keep you up to date on the latest FDA Class 1 and Class 2 recalled drugs and market withdrawals that impact our members. It is one of the many ways we, at Capital Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

WHO WE ARE

Capital Rx is a full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA), advancing our nation's electronic healthcare infrastructure to improve drug price visibility and patient outcomes. As a Certified B Corp™, Capital Rx is executing its mission through the deployment of JUDI®, the company's cloud-native enterprise health platform, and a Single-Ledger Model™, which increases visibility and reduces variability in drug prices. JUDI connects every aspect of the pharmacy ecosystem in one efficient, scalable platform, servicing over 2.4 million members for Medicare, Medicaid, and commercial plans. Together with our clients, we are reimagining the administration of pharmacy benefits and rebuilding trust in healthcare. **The drug recall report is subject to change: information in this report is current as of **7/17/2024****

Privacy Statement:

This privacy policy describes the types of information we may collect from you or that you may provide when you visit the website cap-rx.com and our practices for collecting, using, maintaining, protecting, and disclosing that information. Capital Rx, Inc. ("we," "our," or "us") is committed to ensuring that your privacy is protected. This policy applies to information we may collect through cap-rx.com, including any services offered on or through cap-rx.com such as the prescription benefit member web portal, and our mobile application accessible at the Google Play Store and iOS App Store under the name Capital Rx (collectively, our "Site").

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
7/3/2024	Class 2	Acetaminophen Extra Strength 500 Mg tablets	Contract Pharmacal Corporation	00904-6730-60	368638 EXP 05/2025	Discoloration where some tablets are a brownish color instead of the typical white color.
7/3/2024	Class 2	Zilretta 32 Mg extended-release injectable suspension	Pacira Pharmaceuticals Inc.	65250-0003-01, 65250-0001-01, 65250-0002-01	23-9006 EXP MAR 2025	Failing to meet dissolution specifications.
7/10/2024	Class 2	Allopurinol 300 Mg Tablets	Dr. Reddy's Laboratories, Inc.	55111-0730-01	L2300594	Presence of a foreign substance.
7/10/2024	Class 2	Methylphenidate Hcl Er (Osm) 36 Mg Tablets	Trigen Laboratories	13811-0708-10	230159M EXP 2/28/2026	Failing to meet dissolution specifications, which may result in the tablets not dissolving properly.

How do I find out more information about the recall? View the FDA website URL for more information.

RECALL TYPE	DRUG RECALLED	FDA NOTIFICATION URL
Class 2	Acetaminophen Extra Strength 500 Mg tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=207964
Class 2	Zilretta 32 Mg extended-release injectable suspen-sion	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=208309
Class 2	Allopurinol 300 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=208266
Class 2	Methylphenidate Hcl Er (Osm) 36 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=208402